secwatch.observer — SEC 8-K summary
======================================

Issuer:     Quince Therapeutics, Inc. (QNCX)
CIK:        0001662774
Form:       8-K
Filed at:   2026-07-31T20:50:54+00:00
Accession:  0001193125-26-328784
Event type: leadership
Sentiment:  neutral
Materiality: 0.75
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Quince Therapeutics announces conditional CEO/COO resignations and appointments pending shareholder vote
--------------------------------------------------------------------------------

- CEO Dirk Thye and COO Brendan Hannah tender conditional resignations effective two business days after Sept 25, 2026 special meeting, contingent on stockholder approval of three proposals.
- Board conditionally appoints Brigette Roberts as CEO, John Militello as CFO, and Keith Fandrick as COO, effective at same time.
- Board reduces size from 5 to 4 upon Thye's resignation; intends to appoint independent director.
- Resignations and appointments tied to stockholder vote on conversion proposal, minimum price proposal, and authorized share increase to 275M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1662774/000119312526328784/0001193125-26-328784-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1662774/000119312526328784/d160394d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-328784

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer